This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liang, S. Articles by Dong, C. Search for Related Content PubMed PubMed Citation Articles by Liang, S. Articles by Dong, C.

Targeting Mutant (V600E) B-Raf in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation

¹ Huck Institutes of the Life Sciences and ² Department of Bioengineering, The Pennsylvania State University, University Park, Pennsylvania; Departments of ³ Pharmacology, ⁴ Pathology, and ⁵ Dermatology, The Pennsylvania State University College of Medicine; ⁶ The Foreman Foundation for Melanoma Research; and ⁷ The Penn State Melanoma Therapeutics Program, Hershey, Pennsylvania

Requests for reprints: Cheng Dong, Department of Bioengineering, The Pennsylvania State University, 233 Hallowell Building, University Park, PA 16802. Phone: 814-865-8091; Fax: 814-863-0490; E-mail: cxd23{at}psu.edu.

Polymorphonuclear neutrophils (PMN) facilitate melanoma cell extravasation under dynamic flow conditions by the binding of intercellular adhesion molecule-1 (ICAM-1) on melanoma cells to ß₂ integrins on PMNs, which is mediated by endogenously produced chemokine interleukin 8 (IL-8) from the tumor microenvironment. However, little is known about the role of B-Raf, the most mutated gene in malignant melanomas, in this process. In this study, we investigated the functional importance of B-Raf in melanoma extravasation by using short interfering RNA to reduce expression/activity of mutant ^V600EB-Raf in melanoma. Results indicated that knockdown of mutant ^V600EB-Raf inhibited melanoma cell extravasation in vitro and subsequent lung metastasis development in vivo. Mechanistic studies showed that inhibition of ^V600EB-Raf significantly reduced the constitutive secretion of IL-8 from melanoma cells as well as the capacity of endogenous IL-8 production from the melanoma-PMN microenvironment. Furthermore, a reduction in ICAM-1 expression on melanoma cells was detected following mutant ^V600EB-Raf knockdown. Together, these results suggest that targeting mutant ^V600EB-Raf reduces melanoma cell extravasation by decreasing IL-8 production and interrupting ICAM-1-ß₂ integrin binding of melanoma cells to the endothelium mediated by PMNs in the microcirculation, which provides a rationale and mechanistic basis for targeting mutant ^V600EB-Raf to inhibit melanoma extravasation and subsequent metastasis development. [Cancer Res 2007;67(12):5814–20]

This article has been cited by other articles:

				S. Liang and C. Dong Integrin VLA-4 enhances sialyl-Lewisx/a-negative melanoma adhesion to and extravasation through the endothelium under low flow conditions Am J Physiol Cell Physiol, September 1, 2008; 295(3): C701 - C707. [Abstract] [Full Text] [PDF]

				S. Liang, C. Fu, D. Wagner, H. Guo, D. Zhan, C. Dong, and M. Long Two-dimensional kinetics of {beta}2-integrin and ICAM-1 bindings between neutrophils and melanoma cells in a shear flow Am J Physiol Cell Physiol, March 1, 2008; 294(3): C743 - C753. [Abstract] [Full Text] [PDF]

				S. V. Madhunapantula and G. P. Robertson Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies? Cancer Res., January 1, 2008; 68(1): 5 - 8. [Abstract] [Full Text] [PDF]